Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug wasn't helping patients live longer.
Rhythm announced the presentation of results from a new epidemiology study demonstrating a...
Gilead Sciences Inc. announced results from a Phase 2 clinical trial evaluating idelalisib, an...
Halozyme Therapeutics Inc. has posted results from an early-stage trial that included its drug PEGPH20 as a treatment for pancreatic cancer. Halozyme said PEGPH20 may make tumors more vulnerable to treatment by depleting their defenses and changing their metabolism.
Drug developer Oncothyreon Inc. announced new clinical trial data about an experimental lung cancer treatment that failed to improve the overall survival rate. Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.
The U.S. Food and Drug Administration has granted Priority Review to Janssen's New Drug Application for simeprevir, an investigational NS3/4A protease inhibitor administered with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C.
The Indian government announced the development of a new low-cost vaccine proven effective against a diarrhea-causing virus that is one of the leading causes of childhood deaths across the developing world. The Indian manufacturer of the new rotavirus vaccine pledged to sell it for $1 a dose.
The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory and at Baxter International Inc., a U.S. based healthcare company, revealed it to be promising and well tolerated, according to a research paper published online in The Lancet Infectious Diseases.
Eli Lilly and Co. said it will stop development of an experimental cancer drug after it failed in a late-stage clinical trial.The company was studying enzastaurin as a treatment for diffuse large B-cell lymphoma, a cancer that affects a type of white blood cell.
Pfizer Inc. may not pursue further development of Remoxy, an experimental pain drug that has been plagued with delays in regulatory approval. Durect Corp. developed Remoxy and licensed it to Pain Therapeutics Inc. who in turn sublicensed the drug to Pfizer.
The National Center for Neurology and Psychiatry and drugmaker Nippon Shinyaku Co. will start a clinical trial of a drug to treat Duchenne muscular dystrophy, a genetic disease that affects around one in 3,500 boys, aiming to release it for sale in five years.
Alexza Pharmaceuticals Inc. said Teva Pharmaceutical Industries Ltd. will market its agitation drug Adasuve in the United States. The companies said that Teva will be responsible for all U.S. commercial and clinical-related activities, including a required post-approval study.
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms temporarily.
Baxter International said that a promising new therapy had failed to halt the mental decline caused by the disease in a late-stage clinical trial. The company said its immunoglobulin therapy did not significantly arrest the decline in either cognition or daily functioning when compared with a placebo.
Merck & Co. said that it received U.S. Food and Drug Administration marketing approval for the new combination cholesterol drug Liptruzet, which combines the company's drug Zetia with a generic version of the mega-blockbuster drug Lipitor.
Drug developer Arena Pharmaceuticals Inc. announced that it is withdrawing its application for approval of the weight loss drug Belviq in Europe. The San Diego company also said that it is still waiting for a U.S. decision on the status of the drug.
Allergan executives announced that are delaying late-stage testing of an experimental eye treatment by one to two years. Allergan was previously expected to launch a study of DARP-in, an experimental drug for macular degeneration, by late 2013.
Actavis has acquired a bacterial vaginosis gel developed by Valeant Pharmaceuticals. Actavis said it agreed to pay Valeant $55 million for its metronidazole gel product, which has not yet received marketing approval. The total includes both an upfront payment and payments related to sales targets.
Perosphere and Daiichi Sankyo have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a Phase 1 clinical trial testing the safety, tolerability, and effectiveness of PER977 to reverse the anticoagulant activity of Daiichi Sankyo’s edoxaban.
There’s hope for patients with myotonic dystrophy. A new small-molecule has been shown to break up the protein-RNA clusters that cause the disease in living human cells, an important first step toward developing a pharmaceutical treatment for the as-yet untreatable disease.
Merck & Co. will work with Pfizer Inc. to develop a new combination pill designed to treat Type 2 diabetes. The experimental pill will combine Merck's drug Januvia, Pfizer's experimental pill ertugliflozin, and metformin, an older diabetes drug.
Auxilium Pharmaceuticals Inc. announced the purchase of Actient Holdings LLC from private equity firm GTCR for $585 million. In the process Auxilium said it will get two testosterone drugs, impotence treatments, and two respiratory drugs.
A panel that advises the European Medicines Agency recommended that Avanir Pharmaceuticals' Nuedexta be approved as a treatment for pseudobulbar affect. The drug is already approved in the U.S. Being able to sell the drug in Europe would likely increase Avanir's revenues.
Pfizer Inc. said that the European Union's committee of medical experts has rejected the company's drug Xeljanz for patients with rheumatoid arthritis. The European Medicines Agency committee recommended against approving the drug because its benefits did not sufficiently outweigh its risks.
Pfizer Inc. CEO Ian Read said that continuing expirations of drug patents through 2015 will restrain revenue growth, but the world's largest drugmaker is trying to offset that with launches of several medicines and research to create new ones.
Genzyme announced positive results from a Phase 3 trial of Aubagio designed to assess whether early initiation of the drug in patients who experienced their first neurological symptoms consistent with clinically isolated syndrome can prevent or delay conversion to clinically definite multiple sclerosis.
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease. Now a team of researchers has shown how to exploit tamoxifen’s secondary activities so that it might work on more aggressive breast cancer.
Merck announced that the Food and Drug Administration has designated lambrolizumab as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab's designation as a Breakthrough Therapy is intended to expedite its development and review.